NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia

Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), has entered into an asset purchase option agreement with YOLO Immune to acquire worldwide rights to the YOL104 Program. This program includes YOL104-2, a bioengineered therapy for Ocular Surface Squamous Neoplasia (OSSN). The agreement allows Visara an exclusive option to purchase the program, involving an upfront payment and potential additional payments to YOLO upon exercising the option, although specific financial details were not disclosed.